Addiction Treatment Market Research Report Information By Treatment Type (Alcohol Addiction Treatment, Tobacco/Nicotine Addiction Treatment, Opioid Addiction Treatment, and Other Substances Addiction Treatment), By Drug Type (Bupropion, Varenicline, Acamprosate, Disulfiram, Naltrexone, Methadone, Buprenorphine, Nicotine Replacement Products, and Others), By Treatment Center (Outpatient Treatment Centers, Residential Treatment Centers, and Inpatient Treatment Centers), By Distribution Channel (Hospitals Pharmacies, Medical Stores, and Others

Global Addiction Treatment Market Overview

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Addiction Treatment Market Trends

• Rising drug awareness campaigns and prevention programs and growth in the number of addictions among the population are driving the market growth

Market CAGR for Addiction Treatment is being driven by the rising drug awareness campaigns and prevention programs and growth in the number of addictions among the population. The imposition of lockdowns and pandemic-related restrictions has resulted in the cancellation or delay of diagnoses and treatments for non-COVID and non-urgent medical conditions, including patients dealing with substance and alcohol addiction. A study published in the JAMA Network in November 2021 highlighted the implementation of temporary strategies by federal and state governments in the United States to ensure access to opioid use disorder (OUD) treatment during the pandemic. This involved the adoption of telehealth policies across all states and Washington, DC, leading to an increased demand for substance abuse treatment.

The heightened awareness of substance abuse and drug addiction, coupled with efforts from both private and public entities, is anticipated to drive greater demand for substance abuse treatment. For instance, in December 2021, the Indian government initiated the "Drug-Free India" campaign, focusing on curbing drug abuse in the population. Similarly, in October 2021, the Centers for Disease Control and Prevention (CDC) launched four education campaigns targeting young adults, aged 18-34 years, to prevent drug overdose deaths. These campaigns provide information on fentanyl prevalence and dangers, the risks of mixing drugs, the life-saving potential of naloxone, and the importance of reducing stigma around drug use to support treatment and recovery. Such campaigns and initiatives are enhancing awareness of substance abuse treatment, contributing to the growth of the market.

As a result, it is anticipated that throughout the projection period, demand for the Addiction Treatment Market will increase due to the rising drug awareness campaigns and prevention programs and growth in the number of addictions among the population. Thus, driving the Addiction Treatment Market revenue.

Addiction Treatment Market Segment Insights

Addiction Treatment Market Treatment Type Insights

The Addiction Treatment Market segmentation, based on Treatment Type includes Alcohol Addiction Treatment, Tobacco/Nicotine Addiction Treatment, Opioid Addiction Treatment, and Other Substances Addiction Treatment. The tobacco/nicotine addiction treatment segment dominated the market, accounting for 58% of market revenue (XX Billion). The treatment of tobacco/nicotine addiction involves employing pharmacotherapies and replacement therapies to mitigate dependency on tobacco and nicotine. Recognizing the severe harm caused by tobacco consumption and smoking, as emphasized by the World Health Organization (WHO), which reports that tobacco claims the lives of half of its users. According to WHO in May 2022, tobacco-related fatalities exceed 8 million annually, with over 7 million resulting directly from tobacco use and more than 1.2 million non-smokers succumbing to second-hand smoke exposure. The substantial number of tobacco users and the associated health impact are expected to drive increased demand for tobacco/nicotine addiction treatment, thereby fostering growth in this segment.

Addiction Treatment Market Drug Type Insights

The Addiction Treatment Market segmentation, based on Drug Type includes Bupropion, Varenicline, Acamprosate, Disulfiram, Naltrexone, Methadone, Buprenorphine, Nicotine Replacement Products, and Others. The Bupropion segment dominated the market, accounting for 58% of market revenue (XX Billion). Beyond its role in smoking cessation, Bupropion serves as a prescribed antidepressant. This dual functionality is particularly advantageous for individuals dealing with both depression and nicotine addiction concurrently. The antidepressant properties of Bupropion play a pivotal role in supporting mental health throughout the quitting process, enhancing its overall effectiveness as a therapeutic solution.

Addiction Treatment Market Treatment Center Insights

The Addiction Treatment Market segmentation, based on Treatment centers includes Outpatient Treatment Centers, Residential Treatment Centers, and Inpatient Treatment Centers. The Outpatient Treatment Centers segment dominated the market, accounting for 60% of market revenue (XX Billion). The scheduling flexibility offered by outpatient programs is a key advantage, allowing individuals to attend therapy sessions and counseling at times that align with their unique schedules. This adaptability is especially attractive to those unable to commit to the structured timelines of inpatient programs. Additionally, outpatient treatment enables individuals to stay within their communities while undergoing care. This local integration enhances the support system, with active involvement from friends and family members in the treatment process. The positive aspect of community integration contributes significantly to the overall appeal of outpatient services.

Addiction Treatment Market Distribution Channel Insights

The Addiction Treatment Market segmentation, based on Distribution Channels includes Hospitals Pharmacies, Medical Stores, and Others. The hospital pharmacies segment dominated the market, accounting for 60% of market revenue (XX Billion). A crucial function of hospital pharmacies is the distribution of medication-assisted treatment (MAT), a comprehensive approach combining behavioral therapy and medications to address substance use disorders. The accessibility of MAT within hospital settings amplifies the efficacy of addiction treatment, contributing substantially to the growth of this segment.

Figure 1: Addiction Treatment Market, by Distribution Channel, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Addiction Treatment Market Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The anticipated expansion of the Addiction Treatment market in North America can be attributed to several key factors. The market is driven by the escalating prevalence of tobacco overuse and a surge in governmental initiatives aimed at mitigating substance abuse. For instance, recent data from the Substance Abuse and Mental Health Services Administration (SAMHSA) in 2021 revealed that over 61,203 individuals aged 12 years and above reportedly engaged in illicit drug consumption in the United States. Additionally, data from the Canadian Mental Health Association (CMHA) indicated that an estimated 21% of the Canadian population, exceeding 6 million individuals, would meet the criteria for drug addiction in their lifetime. The substantial prevalence of addiction within the region is expected to generate heightened demand for addiction treatments, thereby propelling market growth.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ADDICTION TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Addiction Treatment Market accounts for the second-largest market share as

Several factors are propelling the growth of the substance abuse treatment market in Europe. These include heightened drug awareness campaigns and prevention programs, a substantial population grappling with addiction, and increased research and development in the field of substance abuse treatment. According to the European Drug Report 2022, an estimated 83.4 million adults (aged 15-64) in the European Union, comprising 29% of the population, were reported to use illicit drugs. Notably, there were more male users (50.5 million) than female users (33.0 million). Cannabis emerged as the most widely consumed substance, with over 22 million European adults acknowledging its use in 2021. The significant prevalence of substance use in the European region is anticipated to drive an increased demand for substance abuse treatment throughout the forecast period. Further, the German Addiction Treatment Market held the largest market share, and the UK Addiction Treatment Market was the fastest-growing market in the European region

The Asia-Pacific Addiction Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. Substance abuse issues, encompassing both alcohol and illicit drugs, have shown a noticeable upward trend across several regions in the Asia Pacific. According to a 2018 report by the World Health Organization (WHO), the per capita consumption of pure alcohol in India surged from 2.4 liters in 2005 to 4.3 liters in 2010 and further to 5.7 liters in 2016. A 2019 government survey revealed that one in seven Indians aged 10-75 engages in alcohol consumption. Significantly, the prevalence is substantially higher among men, with 27.3 percent reporting alcohol use compared to 1.6 percent among women. This escalating pattern of alcohol consumption has led to a growing demand for addiction treatment services. Moreover, China’s Addiction Treatment Market held the largest market share, and the Indian Addiction Treatment Market was the fastest-growing market in the Asia-Pacific region.

Addiction Treatment Market Key Market Players & Competitive Insights 

Leading market players are investing heavily in research and development to expand their product lines, which will help the Addiction Treatment market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Addiction Treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Addiction Treatment industry to benefit clients and increase the market sector. In recent years, the Addiction Treatment industry has offered some of the most significant advantages to individuals grappling with substance abuse, fostering rehabilitation, and supporting their journey towards recovery and improved mental health. Major players in the Addiction Treatment Market, including Alkermes plc, Cipla Ltd., GlaxoSmithKline plc, Pfizer, Inc., Mallinckrodt, Hikma Pharmaceuticals PLC, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, and Indivor Plc are attempting to increase market demand by investing in research and development operations.

GlaxoSmithKline plc is a healthcare enterprise dedicated to the development, manufacturing, and commercialization of a broad portfolio, including general medicines, specialty medicines, and vaccines. The company provides pharmaceutical solutions for various medical conditions such as HIV, respiratory disorders, cancer, immuno-inflammation, anti-viral treatments, central nervous system (CNS) therapies, metabolic disorders, cardiovascular issues, urogenital problems, anti-bacterial, dermatology, and rare diseases. Additionally, GSK offers over-the-counter (OTC) products addressing pain relief, oral health, nutrition, skin health, and gastrointestinal diseases. GSK's vaccine portfolio encompasses a range of diseases, including hepatitis, diphtheria, tetanus, whooping cough, rotavirus, HPV infections, measles, and bacterial meningitis, among others. The company distributes its products globally through channels such as wholesalers, pharmacies, hospitals, physicians, and other healthcare groups. Headquartered in Brentford, Middlesex, the UK, GSK has a presence. In March 2016, GlaxoSmithKline entered into a partnership with 2morrow Inc., the developer of the SmartQuit app, to provide patches to smokers as part of the app's cessation plan.

Indivior Plc specializes in the development and marketing of medications tailored for treating opioid addiction. The company's product portfolio includes Suboxone, a monthly depot and the sole approved film treatment for opioid dependence; Subutex, a mono-buprenorphine sublingual tablet; Sublocade injection; and Nalscue for opioid use disorder. Additionally, Indivior offers Perseris for schizophrenia. The company's pipeline features buprenorphine-based products, including INDV-1000 in the pre-clinical phase and INDV-2000 in Phase I for substance use disorder. AEF0117 is in Phase II for the treatment of cannabis disorder. Indivior delivers its products in various forms such as film, tablets, and Subutex tabs, catering to markets in the US, Australia, Malaysia, France, Italy, Spain, Germany, Canada, and the UK. Headquartered in Slough, the UK, Indivior entered a collaborative agreement in 2022 with Addex Therapeutics, a clinical-stage pharmaceutical company, focusing on the discovery and development of novel oral gamma-aminobutyric acid subtype B (GABAB) Positive Allosteric Modulator (PAM) drug candidates. As part of this agreement, Indivior committed approximately USD 900,000 in additional research funding to Addex Therapeutics.

Key companies in the Addiction Treatment Market include

• Alkermes plc


• Cipla Ltd.


• GlaxoSmithKline plc


• Pfizer, Inc.


• Mallinckrodt


• Hikma Pharmaceuticals PLC


• Orexo AB


• Titan Pharmaceuticals, Inc.


• Teva Pharmaceutical Industries Ltd


• Indivor Plc

Addiction Treatment Industry Developments

October 2022:In 2022, Pfizer, Inc. unveiled a strategic collaboration with Alex Therapeutics to tailor treatments using digital therapeutics. The partnership involves deploying the AI-based platform of Alex Therapeutics to deliver Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) to individuals dealing with nicotine addiction.

January 2023:In January 2023, Tempero Bio received FDA clearance for its investigational new drug (IND) application concerning TMP-301. TMP-301 represents a prospective metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) designed for addressing cocaine use disorders (CUD).

Addiction Treatment Market Segmentation

Addiction Treatment Market Treatment Type Outlook

• Alcohol Addiction Treatment


• Tobacco/Nicotine Addiction Treatment


• Opioid Addiction Treatment


• Other Substances Addiction Treatment

Addiction Treatment Market Drug Type Outlook

• Bupropion


• Varenicline


• Acamprosate


• Disulfiram


• Naltrexone


• Methadone


• Buprenorphine


• Nicotine Replacement Products


• Others

Addiction Treatment Market Treatment Center Outlook

• Outpatient Treatment Centers


• Residential Treatment Centers


• Inpatient Treatment Centers

Addiction Treatment Market Distribution Channel Outlook

• Hospitals Pharmacies


• Medical Stores


• Others

Addiction Treatment Market Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America